Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Holdings Trimmed by Dupont Capital Management Corp

Dupont Capital Management Corp lowered its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating) by 28.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,553 shares of the biopharmaceutical company’s stock after selling 6,201 shares during the quarter. Dupont Capital Management Corp’s holdings in Vanda Pharmaceuticals were worth $244,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. LSV Asset Management boosted its stake in Vanda Pharmaceuticals by 6.2% during the fourth quarter. LSV Asset Management now owns 2,260,482 shares of the biopharmaceutical company’s stock valued at $35,467,000 after buying an additional 131,385 shares in the last quarter. Franklin Resources Inc. bought a new position in Vanda Pharmaceuticals during the third quarter valued at about $546,000. Profit Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 204.6% in the 4th quarter. Profit Investment Management LLC now owns 238,060 shares of the biopharmaceutical company’s stock valued at $3,735,000 after purchasing an additional 159,906 shares during the period. Barclays PLC boosted its position in shares of Vanda Pharmaceuticals by 67.6% in the 3rd quarter. Barclays PLC now owns 56,802 shares of the biopharmaceutical company’s stock valued at $974,000 after purchasing an additional 22,912 shares during the period. Finally, New York State Common Retirement Fund boosted its position in shares of Vanda Pharmaceuticals by 54.9% in the 3rd quarter. New York State Common Retirement Fund now owns 72,266 shares of the biopharmaceutical company’s stock valued at $1,239,000 after purchasing an additional 25,613 shares during the period. 99.12% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ VNDA opened at $11.81 on Monday. Vanda Pharmaceuticals Inc. has a one year low of $10.60 and a one year high of $21.86. The firm has a market capitalization of $660.26 million, a PE ratio of 20.36 and a beta of 0.54. The business has a 50-day moving average price of $12.23 and a two-hundred day moving average price of $15.23.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Rating) last announced its quarterly earnings data on Wednesday, February 23rd. The biopharmaceutical company reported $0.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.03. Vanda Pharmaceuticals had a return on equity of 6.81% and a net margin of 12.34%. The firm had revenue of $68.02 million during the quarter, compared to analyst estimates of $65.90 million. During the same period last year, the company posted $0.15 EPS. On average, equities research analysts forecast that Vanda Pharmaceuticals Inc. will post 0.42 EPS for the current fiscal year.

In other news, CMO Joakim Wijkstrom sold 6,974 shares of the firm’s stock in a transaction dated Wednesday, March 2nd. The stock was sold at an average price of $11.19, for a total transaction of $78,039.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Patrick Moran sold 3,473 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $11.19, for a total value of $38,862.87. The disclosure for this sale can be found here. Insiders have sold a total of 30,015 shares of company stock valued at $334,662 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

A number of equities analysts recently weighed in on VNDA shares. Jefferies Financial Group lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the company from $24.00 to $12.00 in a research report on Friday, February 25th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 8th. StockNews.com upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 26th. Finally, TheStreet lowered Vanda Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Wednesday, February 9th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $18.00.

Vanda Pharmaceuticals Company Profile (Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Articles

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.